<DOC>
	<DOCNO>NCT00049842</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy PEG-Intron versus treatment prevention fibrosis progression adult participant moderate severe liver fibrosis secondary chronic hepatitis C , fail PEG-Intron plus Rebetol treatment protocol P02370 ( NCT00039871 ) .</brief_summary>
	<brief_title>Prevention Disease Progress Chronic Hepatitis C Patients With Liver Fibrosis ( Study P02570AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age entry study P02370 ( NCT00039871 ) 1865 year ; Nonresponder PEGIntron plus Rebetol study P02370 Participants participate P02370 study . Any medical condition , include limited decompensated liver disease , malignancy substance abuse , develop P02370 study could interfere participant 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>